Rainier Therapeutics
www.rainierrx.comRainier Therapeutics is a privately-held biotechnology developing biologics to address medical conditions where there is significant unmet need. Our lead program is a human monoclonal antibody, B-701, that targets and blocks the activity of FGFR3 (fibroblast growth factor receptor 3) and is the most advanced FGFR3-specific antagonist in development.
Read more
Rainier Therapeutics is a privately-held biotechnology developing biologics to address medical conditions where there is significant unmet need. Our lead program is a human monoclonal antibody, B-701, that targets and blocks the activity of FGFR3 (fibroblast growth factor receptor 3) and is the most advanced FGFR3-specific antagonist in development.
Read more
Country
State
California
City (Headquarters)
San Leandro
Industry
Employees
11-50
Estimated Revenue
$1 to $1,000,000
Social
Employees statistics
View all employeesPotential Decision Makers
Chief Medical Officer
Email ****** @****.comPhone (***) ****-****
Technologies
(11)
